This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): amlodipine besylate/atorvastatin calcium
Description: Caduet tablets combine the long-actingcalcium channel blocker Amlodipine besylate with the synthetic lipid-lowering agentAtorvastatin calcium. TheAmlodipine component of Caduet inhibits the transmembrane influx of calcium ions intovascular smooth muscle and cardiac muscle. The Atorvastatin component of Caduet is aselective, competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme thatconverts 3-hydroxy-3-methylglutaryl-coenzyme A to mevalonate, a precursor of sterols,including cholesterol.
Deal Structure: In August 2009, Pfizer Japan and Astellas Pharma announced that the companies reached a co-promotion agreement for a combination drug of hypertension treatment and hypercholesterolemia treatment Caduet Combination Tablets (amlodipine besylate and atorvastatin calcium) in Japan.
Pursuant to this agreement, Pfizer is responsible for manufacturing and sales of Caduet Combination Tablets, and Pfizer and Astellas will co-promote it. Sales will be booked at Pfizer, and Astellas will receive fee in a way that the companies agreed. The term of this agreement is until July 2016.
In July 2011, Pfizer Japan and Astellas announced that the companies reached the change of the co-promotion agreement for a combination drug of hypertension treatment and hypercholesterolemia treatment Caduet Combination Tablets. Pursuant to new agreement, Astellas will hold its distribution rights and book its sales which are currently booked by Pfizer from October 1, 2011. Pfizer will continue to conduct the...See full deal structure in Biomedtracker
Partners: Astellas Pharma, Inc.
Additional information available to subscribers only: